Navigation Links
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018. Biosimilars of these three branded agents are forecasted to erode $8.2 billion in U.S. and European sales in 2018 but they are expected to capture only $4.6 billion in sales due to their lower prices.

"Biosimilars of the five brands covered in this report (Rituxan/MabThera, Erbitux, Herceptin, Amgen's Neupogen and Neulasta) will erode $34.3 billion in brand sales during our 2008-2018 forecast period across the U.S. and Europe and save health care systems $17.3 billion in the process," stated Michael Malecki, Ph.D., analyst and product manager at Decision Resources.

The new special report entitled Biosimilars: G-CSFs and Monoclonal Antibodies in Oncology also finds that oncologists are expected to demand clinical data for biosimilars demonstrating equivalence in multiple subpopulations. That is, although a biosimilar may be labeled for use in multiple subpopulations, oncologists will not feel comfortable prescribing a biosimilar without clinical validation.

Over time, oncologists are expected to become more comfortable using biosimilars in subpopulations and/or indications for which the reference product is approved but not clinically validated. In order to slow the growth of physician comfort in this regard, makers of branded biologics should emphasize the proven efficacy records of their agents and the importance of using a fully validated therapy for patients with life-threatening disease.

"Although surveyed oncologists are the most aggressive in treating cancers, they are hesitant to prescribe a biosimilar if it has not been clinically studied for the indication they are treating, even if the biosimilar is labeled for the indication in question," added Dr. Malecki.

Decision Resources expands the scope and analysis of its biosimilars product line to include oncology, immune and infectious disease and endocrinology/nephrology in three separate reports. The new report series covers 22 key biologic brands from eight biologic classes and include surveys of 456 U.S. and European physicians and 41 managed care organization pharmacy and medical directors.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Biosimilars in Oncology: A Potential $25 Billion in Lost Revenue. This webinar will be held on Thursday, October 8, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GPhA Statement on Introduction of H.R. 1548, The Pathway for Biosimilars Act
2. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
3. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
4. Routine Testing Would Improve Herceptin Use in Breast Cancer
5. Mathematical modeling predicts response to Herceptin
6. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
7. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
8. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
9. Erbitux May Help Some With Colorectal Cancer
10. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
11. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV ... the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream ... Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: ... wait longer to access the treadmills. It’s a predictable trend. After the excesses of ... and get in shape by joining gyms, starting new walking or running routines, or ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
(Date:2/5/2016)... Feb. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... previously announced underwritten secondary offering of 11,027,558 shares of ... of affiliates of Blackstone and Goldman Sachs.  The shares ... price of $96.45 per share. The selling stockholders will ... Zimmer Biomet nor any of its directors, officers or ...
(Date:2/5/2016)... France , Germany ... and Israel ). It includes a 10-year epidemiology forecast ... segmented by age and sex in these markets. GD epidemiology report is ... in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends ... Germany , Italy , Spain ...
Breaking Medicine Technology: